Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

Background: Discontinuation of tyrosine kinase inhibitors (TKIs) is feasible in a subset of CML patients who have maintained a deep molecular response for at least two years. Numerous discontinuation trials have been performed and consistently show approximately 50% of patients relapse after stoppin...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 138; no. Supplement 1; p. 2555
Main Authors Sweet, Kendra, Atallah, Ehab L., Radich, Jerry P., Zhang, Mei-Jie, Sahakian, Eva, Mediavilla-Varela, Melanie, Vistocky, Alexis, Heinrich, Michael C., Thompson, James E., Mauro, Michael J., Flynn, Kathryn E, Baim, Arielle, Pinilla Ibarz, Javier
Format Journal Article
LanguageEnglish
Published Elsevier Inc 23.11.2021
Online AccessGet full text
ISSN0006-4971
1528-0020
DOI10.1182/blood-2021-147954

Cover